Q0234 Insurance Policy Changes

HCPCS Q0234 is officially defined as "Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg." HCPCS Q0234 is referenced in 3 tracked payer policy changes from Kansas Medicaid (KanCare) and Blue Cross Blue Shield of Rhode Island. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q0234 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.